- $250.84m
- $234.90m
- $4.41m
Brief: Ocugen Announces Positive Data And Safety Monitoring Board Review And Initiation Of Enrollment In Medium Dose For Ocu410st—A Modifier Gene Therapy—In Gardian Study For Stargardt Disease
Brief: Ocugen Intends To Restate Financial Statements For The Year Ended December 31, 2022 And For Each Of The First Three Quarters Of 2022 And 2023
Brief: Ocugen, Inc. Appoints Huma Qamar, MD, MPH As Chief Medical Officer
Brief: Ocugen Announces Dosing Completion Of Subjects With Geographic Atrophy In Cohort 1 Of Phase 1/2 Clinical Trial Evaluating Safety, Efficacy Of OCU410
Ocugen Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Ocugen Announces Dosing Completion Of Subjects With Stargardt In Cohort 1 Of Phase 1/2 Clinical Trial
Brief: Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design
Brief: Ocugen Announces Ocu400 Receives Regenerative Medicine Advanced Therapy (Rmat) Designation For Treatment Of Retinitis Pigmentosa Associated With Rho Mutations
Brief: Ocugen Announces First Patient Dosed In Phase 1/2 Clinical Trial of OCU410
Brief: Ocugen Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
Brief: Ocugen - $0.06 Net Loss Per Common Share For Three Months Ended Sept 30, 2023
Ocugen Inc expected to post a loss of 7 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Hyatt Hotels, Walmart, Maxeon
U.S. STOCKS ON THE MOVE-Olema Pharma, Akamai Technologies, US banks
U.S. STOCKS ON THE MOVE-PepsiCo, Electronic Arts, Honeywell
U.S. STOCKS ON THE MOVE-China ADRs, Lexicon Pharma, PepsiCo
Brief: Ocugen Mucosal Vaccine Candidate Ocu500 Selected By Nih/Niaid Project Nextgen
Ocugen rises on vaccine candidate's selection for NIAID clinical trial
Brief: Ocugen Appointed Michael Breininger As Principal Financial Officer